Received Oct 16, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | UNK | — | — |
i have covid; i have covid; allergic to the vaccine; This is a spontaneous report received from a Consumer or other non HCP, Program ID. A patient (age and gender not provided) received BNT162b2 (BNT162B2 NOS), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Mast Cell Activation Syndrome (MCAS)" (unspecified if ongoing); "Interstitial Cystitis (IC)" (unspecified if ongoing); "chronic stomach ulcer" (unspecified if ongoing); "immune comprimsed" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "i have covid"; ALLERGY TO VACCINE (non-serious), outcome "unknown", described as "allergic to the vaccine". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: i have covid, notes: I took home test i have covid. Clinical course: The patient took a home test and had COVID. The patient was allergic to the vaccine. It was advised by Pfizer and Moderna not to get a 3rd shot. Patient had Mast Cell Activation Syndrome (MCAS)/ Interstitial Cystitis (IC) and a chronic stomach ulcer. The patient was immune compromised. The patient was asking that whether COVID medication right or not. The information on the batch/lot number for BNT162b2 will be requested and submitted if and when received.
Medical History/Concurrent Conditions: Cystitis interstitial; Immunocompromised; Mast cell activation syndrome; Stomach ulcer
Test Name: Covid-19; Result Unstructured Data: Test Result:i have covid; Comments: I took home test i have covid